Press releases

2019201820172016201520142013
Press release2019/06/13
Selective effect signal on liver cancer tissue in phase Ia study with MIV-818

Stockholm, Sweden – Medivir AB (Nasdaq, Stockholm: MVIR) today announces the results of an analysis of data from the first six...

Read more
Press release2019/06/04
Medivir to present at the 2019 BIO International Convention

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in...

Read more
Press release2019/06/03
New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Read more
Press release2019/05/27
Medivir to present at the Redeye Pre-ASCO Seminar on May 28

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm....

Read more
Press release2019/05/16
New data from the phase I study of birinapant in combination with Keytruda® will be presented at the ASCO 2019

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Read more
Press release2019/05/13
Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that positive data from the investigator-initiated study evaluating the effects of...

Read more
Press release2019/05/09
Resolutions at the Annual General Meeting in Medivir on 9 May 2019

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing directorThe...

Read more
Press release2019/05/07
Data from the remetinostat phase II study in basal cell carcinoma patients to be presented at the 2019 SID Annual meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that data from the investigator-initiated study evaluating the effects of remetinostat...

Read more
Press release2019/05/06
Safety and efficacy data from the MIV-711 phase II open label extension study presented at the OARSI world congress

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, has...

Read more
Press release2019/05/03
MEDIVIR AB – INTERIM REPORT, JANUARY – MARCH 2019

Clinical studies progress according to plan January – MarchSignificant events during the quarter The phase II study of birinapant in combination...

Read more
Press release2019/04/30
Data from the MIV-711 phase II program to be presented at the OARSI world congress

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, will...

Read more
Press release2019/04/29
Medivir appoints new CFO

Stockholm, Sweden – Medivir AB (Nasdaq Stockholm: MVIR) today announces the appointment of Magnus Christensen as new CFO of Medivir effective...

Read more